HR

Healthcare Realty Trust Inc

Add to Watchlist

Advanced Chart

16.670

-0.2(-1.186%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

16.910

Open

16.870

VWAP

16.72

Vol

4.79M

Mkt Cap

6.30B

Low

16.665

Amount

80.17M

EV/EBITDA(TTM)

108.51

Total Shares

378.54M

10.09B

EV/OCF(TTM)

21.32

P/S(TTM)

4.31

Healthcare Realty Trust Incorporated is a self-managed and self-administered real estate investment trust (REIT) that owns and operates medical outpatient buildings primarily located around hospital campuses. The Company selectively grows its portfolio through property acquisition and development. Its portfolio includes over 650 properties totaling more than 38 million square feet concentrated in 15 growth markets. The Company is engaged in a spectrum of integrated services including leasing, management, acquisition, financing, development and redevelopment of such properties. It focuses on facilities primarily located on or near the campuses of acute care hospitals associated with health systems. It owns properties in high-growth markets with a tenant mix that includes over 30 physician specialties, as well as surgery, imaging, cancer, and diagnostic centers. The Company’s real estate portfolio is leased to a diverse tenant base.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

293.26M

-5.33%

293.91M

-6.82%

292.96M

-7.38%

Estimates Revision

The market is revising Downward the revenue expectations for Healthcare Realty Trust Incorporated (HR) for FY2025, with the revenue forecasts being adjusted by -0.14% over the past three months. During the same period, the stock price has changed by 11.58%.

Revenue Estimates for FY2025

Revise Downward

-0.14%

In Past 3 Month

Stock Price

Go Up

+11.58%

In Past 3 Month

9 Analyst Rating

-0.24% Downside

Wall Street analysts forecast HR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HR is 16.63 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

7 Hold

1 Sell

Hold

-0.24% Downside

Current: 16.670

Low

14.00

Averages

16.63

High

20.00

-0.24% Downside

Current: 16.670

Low

14.00

Averages

16.63

High

20.00

JPMorgan

Neutral

downgrade

$18 -> $17

2025-06-26

Reason

JPMorgan

Price Target

$18 -> $17

2025-06-26

downgrade

Neutral

Reason

JPMorgan lowered the firm's price target on Healthcare Realty Trust to $17 from $18 and keeps a Neutral rating on the shares. The firm updated the company's model.

Wells Fargo

John Kilichowski

Sell

Maintains

$17 → $16

2025-03-10

Reason

Wells Fargo

John Kilichowski

Price Target

$17 → $16

2025-03-10

Maintains

Sell

Reason

Wedbush

Richard Anderson

Hold

Sell

Downgrades

$18 → $16

2025-01-02

Reason

Wedbush

Richard Anderson

Price Target

$18 → $16

2025-01-02

Downgrades

Hold

Sell

Reason

Wedbush downgraded Healthcare Realty Trust to Underperform from Neutral with a price target of $16, down from $18. The company "remains a work in progress" but the stock's trades at a 2-to-3 turn multiple premium to its nearest peer, the analyst tells investors in a research note. The firm says Healthcare Realty resetting leadership may "expend energy that could otherwise be directed toward growing the business."

JP Morgan

Michael Mueller

Buy

Hold

Downgrades

$19

2024-12-20

Reason

JP Morgan

Michael Mueller

Price Target

$19

2024-12-20

Downgrades

Buy

Hold

Reason

JPMorgan downgraded Healthcare Realty Trust to Neutral from Overweight with an unchanged price target of $19. The firm made several rating changes in conjunction with its 2025 real estate investment trust and real estate services outlook. The analyst recognizes that Healthcare Realty management's efforts to drive its multitenant occupancy have been paying off in recent quarters, but says this progress may be overshadowed over the near-term by the company's CEO search and what actions that person might take to shape its go-forward path.

Wells Fargo

James Feldman

Sell

Initiates

$16 → $17

2024-10-01

Reason

Wells Fargo

James Feldman

Price Target

$16 → $17

2024-10-01

Initiates

Sell

Reason

Wells Fargo

Joseph Feldman

Sell

Initiates

$16 → $17

2024-10-01

Reason

Wells Fargo

Joseph Feldman

Price Target

$16 → $17

2024-10-01

Initiates

Sell

Reason

Wells Fargo assumed coverage of Healthcare Realty Trust with an Underweight rating with a price target of $17, up from $16. The entire Healthcare sector has worked in 2024 as it benefits from the secular tailwinds of the often-mentioned acceleration of retirement age individuals, occupancy recovery from COVID, and minimal-to-negative supply growth as development costs and bed moratoriums impede new stock, the firm says. Given the re-rating the space has seen and significant premiums to NAV, Wells sees growth-adjusted multiples as the best method of picking Healthcare stocks today.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Healthcare Realty Trust Inc (HR.N) is -57.32, compared to its 5-year average forward P/E of 17.40. For a more detailed relative valuation and DCF analysis to assess Healthcare Realty Trust Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

17.40

Current PE

-57.32

Overvalued PE

116.84

Undervalued PE

-82.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

16.18

Current EV/EBITDA

14.54

Overvalued EV/EBITDA

19.32

Undervalued EV/EBITDA

13.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

5.85

Current PS

4.30

Overvalued PS

7.38

Undervalued PS

4.33